Germany’s New Government Will Maintain Price Freeze And Slash Free Pricing Period
Big changes are in store on the drug pricing front in Germany. Further reforms could depend on who is appointed health minister.
You may also be interested in...
After years of wrangling, the legislative process for new regulation on greater cooperation on health technology appraisals across the EU has entered its final stages, with parliament expected to adopt the legislation soon.
Drug price freeze introduced in 2010 would remain to 2022, under draft legislation to revise AMNOG reimbursement system. It introduces some limits on the year of free pricing that companies enjoy after launch.
German coalition negotiation proposals will see government slash the obligatory rebate for pharma companies while continuing the current prize freeze. But old products will be exempt from HTA.